We've detected an Ad Blocker in your browser.
Please disable or pause the Ad Blocker and refresh the page to be able to register and access the website normally.
4–6 MAY 2022
15:00–20:00 CEST | 9:00–14:00 EDT
Day 1: Individualising Treatment
Day 2: Complex Phenotypes and Advanced Treatment
Day 3: Beyond Foundational Management
LOG IN
Brought to you by:
Symposia Sessions
This year at HFO, our partners are participating in the scientific programme and will be delivering content through symposia sessions.
The symposia sessions will be broadcast to the audience during exclusive time slots over the three-day programme.
Symposia
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?
Date: Wednesday 4 May 2022
Time: 16:30–17:15 CEST
Panel
Andrew Coats, Biykem Bozkurt, Mikhail Kosiborod
Overview
Taking the recent ACC heart failure guideline updates as its core theme, this symposium will provide a succinct overview of the changes with one of the guideline’s primary authors. We will then consider how guidelines have evolved to accommodate the growing number of foundational treatments for heart failure and how we are moving towards personalised care. We also take a look at HFpEF, and assess how our treatment options have changed and what else can be expected for this population.
Learning objectives
Upon participation in this programme physicians should be able to:
- Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
- Compare updates from the ACC with the 2021 ESC HF guidelines
- Recall guideline recommendations for the initiation of foundational therapy for heart failure
- Adopt foundational GMDT early in the disease course
- Postulate how ejection fraction will be used in future trials and in future guidelines
- Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
This symposium has been funded by an educational grant from AstraZeneca.
This symposium has been submitted to the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) seeking 1 CME point, equating to 1 hour of learning.
WATCH ON-DEMAND
Making Gains in HFpEF: An Appraisal of Where We Are Now
Date: Friday 6 May 2022
Time: 17:40–18:25 CEST
Panel
Carolyn Lam, Javed Butler, Shelley Zieroth
Overview
In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with an left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.
Learning objectives
Upon participation in this programme physicians should be able to:
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. It is not intended for US or UK based healthcare professionals.
This symposium has been submitted to the European Board for Accreditation in Continuing Education for Health Professionals (EBAC) seeking 1 CME point, equating to 1 hour of learning.
WATCH ON-DEMAND
Educational Partners:
